Literature DB >> 31422119

PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers.

Renate M Hoogeveen, Tjerk S J Opstal, Yannick Kaiser, Lotte C A Stiekema, Jeffrey Kroon, Remco J J Knol, Willem A Bax, Hein J Verberne, Jan H Cornel, Erik S G Stroes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31422119     DOI： 10.1016/j.jcmg.2019.06.022

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN： 1876-7591


× No keyword cloud information.
  11 in total

Review 1.  Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall.

Authors:  Sabina Ugovšek; Miran Šebeštjen
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

2.  The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels.

Authors:  Tina Levstek; Nik Podkrajšek; Andreja Rehberger Likozar; Miran Šebeštjen; Katarina Trebušak Podkrajšek
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-22

3.  Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis.

Authors:  Jacob K Jensen; Tina Binderup; Constance E Grandjean; Simon Bentsen; Rasmus S Ripa; Andreas Kjaer
Journal:  Atherosclerosis       Date:  2022-04-04       Impact factor: 6.847

4.  Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease.

Authors:  Renate M Hoogeveen; Simone L Verweij; Yannick Kaiser; Jeffrey Kroon; Hein J Verberne; Liffert Vogt; Sophie J Bernelot Moens; Erik S G Stroes
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

Review 5.  Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review.

Authors:  Na-Qiong Wu; Hui-Wei Shi; Jian-Jun Li
Journal:  Front Cardiovasc Med       Date:  2022-02-18

6.  Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.

Authors:  Thorsten M Leucker; Gary Gerstenblith; Michael Schär; Todd T Brown; Steven R Jones; Yohannes Afework; Robert G Weiss; Allison G Hays
Journal:  J Am Heart Assoc       Date:  2020-07-17       Impact factor: 5.501

Review 7.  Inflammation and cardiovascular disease: From mechanisms to therapeutics.

Authors:  Abdulhamied Alfaddagh; Seth S Martin; Thorsten M Leucker; Erin D Michos; Michael J Blaha; Charles J Lowenstein; Steven R Jones; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2020-11-21

8.  Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study.

Authors:  Thomas Metzner; Deborah R Leitner; Gudrun Dimsity; Felix Gunzer; Peter Opriessnig; Karin Mellitzer; Andrea Beck; Harald Sourij; Tatjana Stojakovic; Hannes Deutschmann; Winfried März; Ulf Landmesser; Marianne Brodmann; Gernot Reishofer; Hubert Scharnagl; Hermann Toplak; Günther Silbernagel
Journal:  Biomedicines       Date:  2022-01-11

Review 9.  Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis.

Authors:  Marianna Puccini; Ulf Landmesser; Ursula Rauch
Journal:  Metabolites       Date:  2022-03-04

Review 10.  Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation.

Authors:  Andrej Ćorović; Christopher Wall; Justin C Mason; James H F Rudd; Jason M Tarkin
Journal:  Curr Cardiol Rep       Date:  2020-08-09       Impact factor: 3.955
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.